首页 > 最新文献

Current Cardiovascular Risk Reports最新文献

英文 中文
Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis 转甲状腺素心脏淀粉样变性的种族和民族差异
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-04-04 DOI: 10.1007/s12170-021-00670-y
Gabriela Spencer‐Bonilla, Joyce N. Njoroge, K. Pearson, R. Witteles, M. Aras, K. Alexander
{"title":"Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis","authors":"Gabriela Spencer‐Bonilla, Joyce N. Njoroge, K. Pearson, R. Witteles, M. Aras, K. Alexander","doi":"10.1007/s12170-021-00670-y","DOIUrl":"https://doi.org/10.1007/s12170-021-00670-y","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2021-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-021-00670-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48363681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications 心律失常性心肌病:机制、遗传学及其临床意义
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-03-26 DOI: 10.1007/s12170-021-00669-5
C. Reuter, Annika M. Dries, V. Parikh
{"title":"Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications","authors":"C. Reuter, Annika M. Dries, V. Parikh","doi":"10.1007/s12170-021-00669-5","DOIUrl":"https://doi.org/10.1007/s12170-021-00669-5","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2021-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-021-00669-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41493607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Methods to Optimize Cryoballoon Ablation for Atrial Fibrillation to Minimize Risk of Adverse Outcomes and Arrhythmia Recurrences 优化心房颤动冷冻球囊消融的方法,以最大限度地降低不良结果和心律失常复发的风险
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-03-13 DOI: 10.1007/s12170-021-00668-6
J. Andrade
{"title":"Methods to Optimize Cryoballoon Ablation for Atrial Fibrillation to Minimize Risk of Adverse Outcomes and Arrhythmia Recurrences","authors":"J. Andrade","doi":"10.1007/s12170-021-00668-6","DOIUrl":"https://doi.org/10.1007/s12170-021-00668-6","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2021-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-021-00668-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45236528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Approaches to Risk Stratification of In-Hospital Cardiac Arrest 院内心脏骤停风险分层的新方法
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-31 DOI: 10.1007/s12170-021-00667-7
Jason J Yang, Xiao Hu, N. Boyle, Duc H. Do
{"title":"Novel Approaches to Risk Stratification of In-Hospital Cardiac Arrest","authors":"Jason J Yang, Xiao Hu, N. Boyle, Duc H. Do","doi":"10.1007/s12170-021-00667-7","DOIUrl":"https://doi.org/10.1007/s12170-021-00667-7","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2021-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-021-00667-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46138666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Novel Approaches to Risk Assessment for Ventricular Tachycardia Induction and Therapy 室性心动过速诱发和治疗风险评估的新方法
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-11 DOI: 10.1007/s12170-020-00666-0
Yuki Ishidoya, R. Ranjan
{"title":"Novel Approaches to Risk Assessment for Ventricular Tachycardia Induction and Therapy","authors":"Yuki Ishidoya, R. Ranjan","doi":"10.1007/s12170-020-00666-0","DOIUrl":"https://doi.org/10.1007/s12170-020-00666-0","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 1","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-020-00666-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42011083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Digital Technologies for Blood Pressure Monitoring and Hypertension Management. 血压监测和高血压管理的新型数字技术。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-01 DOI: 10.1007/s12170-021-00672-w
Allison J Hare, Neel Chokshi, Srinath Adusumalli

Purpose of review: Hypertension is common, impacting an estimated 108 million US adults, and deadly, responsible for the deaths of one in six adults annually. Optimal management includes frequent blood pressure monitoring and antihypertensive medication titration, but in the traditional office-based care delivery model, patients have their blood pressure measured only intermittently and in a way that is subject to misdiagnosis with white coat or masked hypertension. There is a growing opportunity to leverage our expanding repository of digital technology to reimagine hypertension care delivery. This paper reviews existing and emerging digital tools available for hypertension management, as well as behavioral economic insights that could supercharge their impact.

Recent findings: Digitally connected blood pressure monitors offer an alternative to office-based blood pressure monitoring. A number of cuffless blood pressure monitors are in development but require further validation before they can be deployed for widespread clinical use. Patient-facing hubs and applications offer a means to transmit blood pressure data to clinicians. Though artificial intelligence could allow for curation of this data, its clinical use for hypertension remains limited to assessing risk factors at this time. Finally, text-based and telemedicine platforms are increasingly being employed to translate hypertension data into clinical outcomes with promising results.

Summary: The digital management of hypertension shows potential as an avenue for increasing patient engagement and improving clinical efficiency and outcomes. It is important for clinicians to understand the benefits, limitations, and future directions of digital health to optimize management of hypertension.

综述目的:高血压是一种常见的疾病,影响了大约1.08亿美国成年人,并且是致命的,每年有六分之一的成年人死亡。最佳管理包括频繁的血压监测和抗高血压药物滴定,但在传统的以办公室为基础的护理模式中,患者只是间歇性地测量血压,而且这种方式容易被误诊为白大褂或隐蔽性高血压。利用我们不断扩大的数字技术资源库来重新构想高血压护理服务的机会越来越大。本文回顾了现有的和新兴的用于高血压管理的数字工具,以及可能增强其影响的行为经济学见解。最近的研究发现:数字连接的血压监测仪为办公室血压监测提供了另一种选择。许多无袖带血压监测仪正在开发中,但在广泛应用于临床之前,还需要进一步的验证。面向患者的中心和应用程序提供了一种向临床医生传输血压数据的方法。尽管人工智能可以对这些数据进行管理,但目前它在高血压的临床应用仍然局限于评估风险因素。最后,基于文本和远程医疗平台越来越多地被用于将高血压数据转化为临床结果,并取得了有希望的结果。总结:高血压的数字化管理显示出提高患者参与度和改善临床效率和结果的潜力。对于临床医生来说,了解数字健康的好处、局限性和未来发展方向,以优化高血压的管理是很重要的。
{"title":"Novel Digital Technologies for Blood Pressure Monitoring and Hypertension Management.","authors":"Allison J Hare,&nbsp;Neel Chokshi,&nbsp;Srinath Adusumalli","doi":"10.1007/s12170-021-00672-w","DOIUrl":"https://doi.org/10.1007/s12170-021-00672-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypertension is common, impacting an estimated 108 million US adults, and deadly, responsible for the deaths of one in six adults annually. Optimal management includes frequent blood pressure monitoring and antihypertensive medication titration, but in the traditional office-based care delivery model, patients have their blood pressure measured only intermittently and in a way that is subject to misdiagnosis with white coat or masked hypertension. There is a growing opportunity to leverage our expanding repository of digital technology to reimagine hypertension care delivery. This paper reviews existing and emerging digital tools available for hypertension management, as well as behavioral economic insights that could supercharge their impact.</p><p><strong>Recent findings: </strong>Digitally connected blood pressure monitors offer an alternative to office-based blood pressure monitoring. A number of cuffless blood pressure monitors are in development but require further validation before they can be deployed for widespread clinical use. Patient-facing hubs and applications offer a means to transmit blood pressure data to clinicians. Though artificial intelligence could allow for curation of this data, its clinical use for hypertension remains limited to assessing risk factors at this time. Finally, text-based and telemedicine platforms are increasingly being employed to translate hypertension data into clinical outcomes with promising results.</p><p><strong>Summary: </strong>The digital management of hypertension shows potential as an avenue for increasing patient engagement and improving clinical efficiency and outcomes. It is important for clinicians to understand the benefits, limitations, and future directions of digital health to optimize management of hypertension.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 8","pages":"11"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-021-00672-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10651630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
"Can you see my screen?" Addressing Racial and Ethnic Disparities in Telehealth. “你能看到我的屏幕吗?”消除远程保健中的种族和族裔差异。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-01 Epub Date: 2021-12-06 DOI: 10.1007/s12170-021-00685-5
Norrisa Haynes, Agnes Ezekwesili, Kathryn Nunes, Edvard Gumbs, Monique Haynes, JaBaris Swain

Purpose of review: Telehealth is an innovative approach with great potential to bridge the healthcare delivery gap, especially for underserved communities. While minority populations represent a target audience that could benefit significantly from this modern solution, little of the existing literature speaks to its acceptability, accessibility, and overall effectiveness in underserved populations. Here, we review the various challenges and achievements of contemporary telehealth and explore its impact on care delivery as an alternative or adjunct to traditional healthcare delivery systems.

Recent findings: Given the COVID-19 pandemic, there has been a rapid acceleration in telemedicine adoption. Recent studies of telemedicine utilization during the pandemic reveal stark disparities in telemedicine modality use based on race, socioeconomic status, geography, and age.

Summary: While telehealth has great potential to overcome healthcare obstacles, the digital divide stands as a challenge to equitable telehealth and telemedicine adoption. Achieving health equity in telehealth will require the mobilization of resources, financial incentives, and political will among hospital systems, insurance companies, and government officials.

审查目的:远程保健是一种具有巨大潜力的创新办法,可弥合保健服务差距,特别是对服务不足的社区而言。虽然少数群体代表了可以从这种现代解决方案中显著受益的目标受众,但现有文献很少谈到它在服务不足人群中的可接受性、可及性和总体有效性。在这里,我们回顾了当代远程医疗的各种挑战和成就,并探讨了其作为传统医疗保健服务系统的替代或辅助手段对医疗服务的影响。最近的发现:鉴于2019冠状病毒病大流行,远程医疗的采用迅速加速。最近关于大流行期间远程医疗使用情况的研究表明,基于种族、社会经济地位、地理位置和年龄,远程医疗方式的使用存在明显差异。摘要:虽然远程保健具有克服保健障碍的巨大潜力,但数字鸿沟对公平采用远程保健和远程医疗构成挑战。实现远程医疗中的卫生公平将需要调动资源、财政激励以及医院系统、保险公司和政府官员之间的政治意愿。
{"title":"\"Can you see my screen?\" Addressing Racial and Ethnic Disparities in Telehealth.","authors":"Norrisa Haynes,&nbsp;Agnes Ezekwesili,&nbsp;Kathryn Nunes,&nbsp;Edvard Gumbs,&nbsp;Monique Haynes,&nbsp;JaBaris Swain","doi":"10.1007/s12170-021-00685-5","DOIUrl":"https://doi.org/10.1007/s12170-021-00685-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Telehealth is an innovative approach with great potential to bridge the healthcare delivery gap, especially for underserved communities. While minority populations represent a target audience that could benefit significantly from this modern solution, little of the existing literature speaks to its acceptability, accessibility, and overall effectiveness in underserved populations. Here, we review the various challenges and achievements of contemporary telehealth and explore its impact on care delivery as an alternative or adjunct to traditional healthcare delivery systems.</p><p><strong>Recent findings: </strong>Given the COVID-19 pandemic, there has been a rapid acceleration in telemedicine adoption. Recent studies of telemedicine utilization during the pandemic reveal stark disparities in telemedicine modality use based on race, socioeconomic status, geography, and age.</p><p><strong>Summary: </strong>While telehealth has great potential to overcome healthcare obstacles, the <i>digital divide</i> stands as a challenge to equitable telehealth and telemedicine adoption. Achieving health equity in telehealth will require the mobilization of resources, financial incentives, and political will among hospital systems, insurance companies, and government officials.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 12","pages":"23"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39720974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 29
Management of Pulmonary Arterial Hypertension. 肺动脉高压的处理。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-01 Epub Date: 2020-11-18 DOI: 10.1007/s12170-020-00663-3
Jennalyn D Mayeux, Irene Z Pan, John Dechand, Joshua A Jacobs, Tara L Jones, Stephen H McKellar, Emily Beck, Nathan D Hatton, John J Ryan

Purpose of review: This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options for PAH.

Recent findings: The paradigm for the optimal management of PAH has shifted in recent years. Upfront combination therapy with an endothelin receptor antagonist and a phosphodiesterase 5 inhibitor is now widely accepted as standard of care. In addition, there is increasing emphasis on starting prostanoids early in order to delay time to clinical worsening. However, less is known regarding which prostanoid agent to initiate and the optimum time to do so. In order to facilitate shared decision-making, there is an increasing need for decision tools based on guidelines and collective clinical experiences to navigate between pharmacologic and interventional treatments, as well as explore innovative, therapeutic pathways for PAH.

Summary: The management of PAH has become increasingly complex. With a growing number of PAH-specific therapies, intimate knowledge of the therapeutics and the potential barriers to adherence are integral to providing optimal care for this high-risk patient population. While current PAH-specific therapies largely mediate their effects through pulmonary vasodilation, ongoing research efforts are focused on ways to disrupt the mechanisms leading to pulmonary vascular remodeling. By targeting aberrations identified in the metabolism and proliferative state of pulmonary vascular cells, novel PAH treatment pathways may be just on the horizon.

综述目的:本综述的重点是1组肺动脉高压(PAH)的治疗管理和个体化方法,利用美国食品和药物管理局批准的PAH特异性治疗和各种介入和手术治疗方案。最近的发现:近年来,PAH的最佳管理模式发生了变化。内皮素受体拮抗剂和磷酸二酯酶5抑制剂的前期联合治疗现在被广泛接受为标准治疗。此外,人们越来越重视尽早开始前列腺素治疗,以延缓临床恶化的时间。然而,关于启动哪种前列腺素药物和最佳时间知之甚少。为了促进共同决策,越来越需要基于指南和集体临床经验的决策工具,以便在药物治疗和介入治疗之间进行导航,并探索创新的PAH治疗途径。摘要:多环芳烃的管理变得越来越复杂。随着多环芳烃特异性治疗方法的不断增加,对治疗方法的深入了解和依从性的潜在障碍对于为这一高危患者群体提供最佳护理是不可或缺的。虽然目前的多环芳烃特异性治疗主要通过肺血管舒张介导其作用,但正在进行的研究工作主要集中在破坏导致肺血管重塑的机制的方法上。通过靶向在肺血管细胞的代谢和增殖状态中发现的畸变,新的多环芳烃治疗途径可能刚刚出现。
{"title":"Management of Pulmonary Arterial Hypertension.","authors":"Jennalyn D Mayeux,&nbsp;Irene Z Pan,&nbsp;John Dechand,&nbsp;Joshua A Jacobs,&nbsp;Tara L Jones,&nbsp;Stephen H McKellar,&nbsp;Emily Beck,&nbsp;Nathan D Hatton,&nbsp;John J Ryan","doi":"10.1007/s12170-020-00663-3","DOIUrl":"https://doi.org/10.1007/s12170-020-00663-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options for PAH.</p><p><strong>Recent findings: </strong>The paradigm for the optimal management of PAH has shifted in recent years. Upfront combination therapy with an endothelin receptor antagonist and a phosphodiesterase 5 inhibitor is now widely accepted as standard of care. In addition, there is increasing emphasis on starting prostanoids early in order to delay time to clinical worsening. However, less is known regarding which prostanoid agent to initiate and the optimum time to do so. In order to facilitate shared decision-making, there is an increasing need for decision tools based on guidelines and collective clinical experiences to navigate between pharmacologic and interventional treatments, as well as explore innovative, therapeutic pathways for PAH.</p><p><strong>Summary: </strong>The management of PAH has become increasingly complex. With a growing number of PAH-specific therapies, intimate knowledge of the therapeutics and the potential barriers to adherence are integral to providing optimal care for this high-risk patient population. While current PAH-specific therapies largely mediate their effects through pulmonary vasodilation, ongoing research efforts are focused on ways to disrupt the mechanisms leading to pulmonary vascular remodeling. By targeting aberrations identified in the metabolism and proliferative state of pulmonary vascular cells, novel PAH treatment pathways may be just on the horizon.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 1","pages":"2"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-020-00663-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38631485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials. 将语音技术和虚拟助手纳入心血管护理和临床试验的可行性。
IF 2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2021-01-01 Epub Date: 2021-06-20 DOI: 10.1007/s12170-021-00673-9
Pishoy Gouda, Elie Ganni, Peter Chung, Varinder Kaur Randhawa, Guillaume Marquis-Gravel, Robert Avram, Justin A Ezekowitz, Abhinav Sharma

Purpose of review: With the rising cost of cardiovascular clinical trials, there is interest in determining whether new technologies can increase cost effectiveness. This review focuses on current and potential uses of voice-based technologies, including virtual assistants, in cardiovascular clinical trials.

Recent findings: Numerous potential uses for voice-based technologies have begun to emerge within cardiovascular medicine. Voice biomarkers, subtle changes in speech parameters, have emerged as a potential tool to diagnose and monitor many cardiovascular conditions, including heart failure, coronary artery disease, and pulmonary hypertension. With the increasing use of virtual assistants, numerous pilot studies have examined whether these devices can supplement initiatives to promote transitional care, physical activity, smoking cessation, and medication adherence with promising initial results. Additionally, these devices have demonstrated the ability to streamline data collection by administering questionnaires accurately and reliably. With the use of these technologies, there are several challenges that must be addressed before wider implementation including respecting patient privacy, maintaining regulatory standards, acceptance by patients and healthcare providers, determining the validity of voice-based biomarkers and endpoints, and increased accessibility.

Summary: Voice technology represents a novel and promising tool for cardiovascular clinical trials; however, research is still required to understand how it can be best harnessed.

审查目的:随着心血管临床试验成本的不断增加,人们希望确定新技术是否能提高成本效益。本综述重点关注语音技术(包括虚拟助手)在心血管临床试验中的当前和潜在用途:语音技术的许多潜在用途已开始在心血管医学中出现。语音生物标志物(语音参数的微妙变化)已成为诊断和监测心衰、冠心病和肺动脉高压等多种心血管疾病的潜在工具。随着虚拟助手的使用日益广泛,许多试验性研究对这些设备是否能辅助促进过渡护理、体育锻炼、戒烟和坚持服药的措施进行了研究,并取得了令人鼓舞的初步成果。此外,这些设备还证明了通过准确可靠地实施问卷调查来简化数据收集的能力。总结:语音技术是心血管临床试验中一种新颖且前景广阔的工具;然而,要了解如何才能最好地利用它,仍需开展研究。
{"title":"Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials.","authors":"Pishoy Gouda, Elie Ganni, Peter Chung, Varinder Kaur Randhawa, Guillaume Marquis-Gravel, Robert Avram, Justin A Ezekowitz, Abhinav Sharma","doi":"10.1007/s12170-021-00673-9","DOIUrl":"10.1007/s12170-021-00673-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>With the rising cost of cardiovascular clinical trials, there is interest in determining whether new technologies can increase cost effectiveness. This review focuses on current and potential uses of voice-based technologies, including virtual assistants, in cardiovascular clinical trials.</p><p><strong>Recent findings: </strong>Numerous potential uses for voice-based technologies have begun to emerge within cardiovascular medicine. Voice biomarkers, subtle changes in speech parameters, have emerged as a potential tool to diagnose and monitor many cardiovascular conditions, including heart failure, coronary artery disease, and pulmonary hypertension. With the increasing use of virtual assistants, numerous pilot studies have examined whether these devices can supplement initiatives to promote transitional care, physical activity, smoking cessation, and medication adherence with promising initial results. Additionally, these devices have demonstrated the ability to streamline data collection by administering questionnaires accurately and reliably. With the use of these technologies, there are several challenges that must be addressed before wider implementation including respecting patient privacy, maintaining regulatory standards, acceptance by patients and healthcare providers, determining the validity of voice-based biomarkers and endpoints, and increased accessibility.</p><p><strong>Summary: </strong>Voice technology represents a novel and promising tool for cardiovascular clinical trials; however, research is still required to understand how it can be best harnessed.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 8","pages":"13"},"PeriodicalIF":2.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9206386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Management of Pulmonary Arterial Hypertension 修正为:肺动脉高压的处理
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2020-11-27 DOI: 10.1007/s12170-020-00665-1
Jennalyn D. Mayeux, Irene Z. Pan, John Dechand, J. A. Jacobs, Tara L Jones, S. McKellar, E. Beck, Nathan D. Hatton, J. Ryan
{"title":"Correction to: Management of Pulmonary Arterial Hypertension","authors":"Jennalyn D. Mayeux, Irene Z. Pan, John Dechand, J. A. Jacobs, Tara L Jones, S. McKellar, E. Beck, Nathan D. Hatton, J. Ryan","doi":"10.1007/s12170-020-00665-1","DOIUrl":"https://doi.org/10.1007/s12170-020-00665-1","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"15 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2020-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12170-020-00665-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42629692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Cardiovascular Risk Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1